Head-to-head · WeighScore
Nouri vs Remedy Meds
The verdict
Remedy Meds takes it — 55.6/100 to 54.8/100, but only just.
Remedy Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth provider offering compounded semaglutide and tirzepatide programs. Nouri is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Nouri | Remedy Meds |
|---|---|---|
| WeighScore | 54.8/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #455 | #437 |
| Semaglutide | Not disclosed | $299/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $399/mo (starting dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #455 · C
Strengths
- Named clinical MSO partner (Wasef Health, PC; Michael Wasef, MD) with public contact email
- Named 503A compounding pharmacy partner (Jungle Jim's Pharmacy, Fairfield OH) with full address
- Available in all 50 states per the FAQ
- Flat per-dose pricing within each tier — no dose-escalation surcharge
- Nutrition and movement coaching included in the medication price
Where it loses points
- Compounded medications only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
- Operating entity name not disclosed in the Terms of Service
- Terms 'where we operate' language is slightly weaker than the FAQ's all-50-states claim
- Video visit required in some states, but those states aren't listed
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #437 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- Limited public information on program details
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.